News about "Pfizer"

Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC

Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.

Pfizer | 30/05/2026 | By News Bureau

Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development

Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.

Pfizer | 29/05/2026 | By News Bureau

Pfizer Reports Positive Phase 2 Results for Pediatric Pneumococcal Vaccine Program

Pfizer reports strong phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing enhanced serotype 3 immune response, broad protection across 25 serotypes, and a favorable safety profile ahead of Phase 3 development.

Pfizer | 20/05/2026 | By News Bureau

Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma

Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).

Pfizer | 01/05/2026 | By News Bureau

Pfizer Reaches Three Settlement Deals for VYNDAMAX

Pfizer reaches three settlement agreements for VYNDAMAX, extending US patent exclusivity to June 1, 2031, subject to the outcome of other litigation.

Pfizer | 30/04/2026 | By News Bureau |  163

Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy

Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.

Pfizer | 24/03/2026 | By News Bureau

Pfizer Joins BaseLaunch Biotech Incubator

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures.

Pfizer | 12/02/2026 | By News Bureau |  279

Pfizer Launches Cost Savings Programme on TrumpRx

Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.

Pfizer | 07/02/2026 | By News Bureau |  191

UK Industry Body Finds Sanofi in Breach Over RSV Therapy Claims Against Pfizer

A UK pharmaceutical industry watchdog has ruled that Sanofi breached the country’s code of practice by making misleading claims about its respiratory syncytial virus (RSV) therapy in comparison with a rival product from Pfizer.

Pfizer | 04/02/2026 | By Darshana |  179

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Pfizer | 04/02/2026 | By News Bureau |  286